Palisade Bio Announces Topline Data From Phase 1b Clinical Study Evaluating PALI-2108, Once-Daily Oral PDE4 Inhibitor Prodrug To Be Selectively Bioactivated In Ileum And Colon, In Patients With FSCD

Palisade Bio, Inc. announced positive topline data from its Phase 1b clinical study of PALI-2108, a once-daily oral PDE4 inhibitor prodrug for fibrostenotic Crohn's disease. The study showed a 47.5% reduction in SES-CD score, with 40% of patients achieving endoscopic response and remission, and demonstrated favorable safety with no serious adverse events. The company plans to advance PALI-2108 into a Phase 2 trial targeting moderate to severe Crohn's disease, aiming to evaluate its anti-fibrotic effects.